A Phase I, Randomized, Double-Blind, Parallel-Group, Study to Assess the Pharmacokinetics and Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects Following A Single Administrations and After Chronic Administration for 7 Days
Phase of Trial: Phase I
Latest Information Update: 18 May 2018
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary) ; Formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Pearl Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 28 Nov 2017 Status changed from recruiting to completed.
- 18 Aug 2017 Planned End Date changed from 1 Aug 2017 to 28 Sep 2017.